Cargando…
Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?
Breast cancer cells preferentially metastasise to the skeleton, owing, in part, to the fertile environment provided by bone. Increased bone turnover releases growth factors that promote tumour cell growth. In turn, tumour cells release factors that stimulate further bone turnover, resulting in a vic...
Autores principales: | von Moos, Roger, Haynes, Ian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470230/ https://www.ncbi.nlm.nih.gov/pubmed/26237064 http://dx.doi.org/10.3390/jcm2030089 |
Ejemplares similares
-
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries
por: von Moos, Roger, et al.
Publicado: (2017) -
Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?
por: Ottewell, Penny, et al.
Publicado: (2019) -
Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?
por: Newton, Emma E., et al.
Publicado: (2022) -
RANKL/RANK: from bone loss to the prevention of breast cancer
por: Sigl, Verena, et al.
Publicado: (2016) -
National medical research ranking and scientific productivity: Where do we stand?
por: Aminpour, Farzaneh
Publicado: (2012)